Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas.

El-Galaly TC, Cheah CY, Kristensen D, Hutchison A, Hay K, Callréus T, Villa D.

Acta Oncol. 2020 Mar 19:1-9. doi: 10.1080/0284186X.2020.1741680. [Epub ahead of print]

PMID:
32189546
2.

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.

Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC.

Br J Haematol. 2020 Feb 4. doi: 10.1111/bjh.16425. [Epub ahead of print]

PMID:
32017050
3.

Mantle cell lymphoma - where precision medicine based on response-adapted treatment strategies could show its full worth.

El-Galaly TC, Cheah CY.

Br J Haematol. 2020 Jan 30. doi: 10.1111/bjh.16396. [Epub ahead of print] No abstract available.

PMID:
31997341
4.

An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement.

Sunderland AJ, Steiner RE, Al Zahrani M, Pinnix CC, Dabaja BS, Gunther JR, Nastoupil LJ, Jerkeman M, Joske D, Cull G, El-Galaly T, Villa D, Cheah CY.

Cancer Med. 2020 Jan;9(2):663-670. doi: 10.1002/cam4.2732. Epub 2019 Dec 5.

5.

Author reply.

Trotman J, Cheah CY, Marlton P, Opat S.

Intern Med J. 2019 Oct;49(10):1338-1339. doi: 10.1111/imj.14460. No abstract available.

PMID:
31602775
6.

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.

Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G.

Blood Adv. 2019 Oct 8;3(19):2804-2811. doi: 10.1182/bloodadvances.2019000458.

7.

Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia.

Van Der Nest BM, Leslie C, Joske D, Radeski D, White R, Cheah CY.

Am J Clin Pathol. 2019 Nov 4;152(6):818-827. doi: 10.1093/ajcp/aqz109. Review.

PMID:
31433844
8.

Refractory α/β-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review.

Lewis KL, Spagnolo D, Radeski D, Cheah CY.

Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):e564-e567. doi: 10.1016/j.clml.2019.05.014. Epub 2019 May 29. No abstract available.

PMID:
31362868
9.

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.

Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, Gould C, Birch S, Sehn LH, Sovani V, Ward MS, Augustson B, Biccler J, Connors JM, Scott DW, Gandhi MK, Savage KJ, El-Galaly T, Villa D, Cheah CY.

Blood Adv. 2019 Jul 9;3(13):2013-2021. doi: 10.1182/bloodadvances.2019000251.

10.

Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.

Wight JC, Yue M, Keane C, Johnston A, Linton K, Chin C, Wai SH, Talaulikar D, Gasiorowski R, Cheah CY, Gregory GP, Dickinson M, Minson A, Coombes C, Ku M, Lam S, Hawkes EA.

Br J Haematol. 2019 Oct;187(2):174-184. doi: 10.1111/bjh.16064. Epub 2019 Jun 24.

PMID:
31236941
11.

Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations.

Ong DM, Ashby M, Grigg A, Gard G, Ng ZY, Huang HE, Chong YS, Cheah CY, Devitt B, Chong G, Loh Z, Mo A, Hawkes EA.

Br J Haematol. 2019 Oct;187(1):73-81. doi: 10.1111/bjh.16049. Epub 2019 Jun 17.

PMID:
31206608
12.

Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls.

El-Galaly TC, Cheah CY, Villa D.

Br J Haematol. 2019 Aug;186(3):409-419. doi: 10.1111/bjh.15965. Epub 2019 May 29. Review.

PMID:
31140600
13.

Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.

Chin CK, Hall S, Green C, Van Hazel G, Spagnolo D, Cheah CY.

Eur J Cancer. 2019 Jul;115:84-87. doi: 10.1016/j.ejca.2019.04.026. Epub 2019 May 23. No abstract available.

PMID:
31129384
14.

Management of patients with follicular lymphoma treated first line with obinutuzumab.

Opat S, Dickinson M, Cheah CY, Tam C, Boulos J, Thorburn AN, Trotman J.

Asia Pac J Clin Oncol. 2019 May;15 Suppl 3:3-11. doi: 10.1111/ajco.13153. Erratum in: Asia Pac J Clin Oncol. 2019 Oct;15(5):e204.

PMID:
31058467
15.

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.

Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS.

Blood Adv. 2019 May 14;3(9):1356-1367. doi: 10.1182/bloodadvances.2018029140.

16.

A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.

Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY.

Hematol Oncol. 2019 Aug;37(3):253-260. doi: 10.1002/hon.2618. Epub 2019 May 24.

PMID:
30983008
17.

Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.

Cheah CY, Opat S, Trotman J, Marlton P.

Intern Med J. 2019 Sep;49(9):1070-1080. doi: 10.1111/imj.14268. Review.

PMID:
30816618
18.

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY.

Ann Hematol. 2019 May;98(5):1169-1176. doi: 10.1007/s00277-018-3571-7. Epub 2019 Jan 8.

PMID:
30617643
19.

Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.

Trotman J, Cheah CY, Marlton P, Opat S.

Intern Med J. 2019 Apr;49(4):422-433. doi: 10.1111/imj.14113. Review.

PMID:
30230156
20.

FDG-PET/CT in the management of lymphomas: current status and future directions.

El-Galaly TC, Villa D, Gormsen LC, Baech J, Lo A, Cheah CY.

J Intern Med. 2018 Oct;284(4):358-376. doi: 10.1111/joim.12813. Epub 2018 Jul 24. Review.

PMID:
29989234
21.

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis.

Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY.

Oncotarget. 2018 Jun 22;9(48):28897-28902. doi: 10.18632/oncotarget.25622. eCollection 2018 Jun 22.

22.

Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.

Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY.

Br J Haematol. 2019 Apr;185(2):334-338. doi: 10.1111/bjh.15444. Epub 2018 Jul 5. No abstract available.

PMID:
29978452
23.

Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement.

Chin CK, Tsang E, Mediwake H, Khair W, Biccler J, Hapgood G, Mollee P, Nizich Z, Joske D, Radeski D, Cull G, Villa D, El-Galaly TC, Cheah CY.

Br J Haematol. 2019 Mar;184(5):826-828. doi: 10.1111/bjh.15173. Epub 2018 Apr 20. No abstract available.

PMID:
29676487
24.

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D.

Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073. Epub 2018 Feb 21.

25.

Novel agents for relapsed and refractory follicular lymphoma.

Cheah CY, Fowler NH.

Best Pract Res Clin Haematol. 2018 Mar;31(1):41-48. doi: 10.1016/j.beha.2017.11.003. Epub 2017 Nov 16. Review.

PMID:
29452665
26.

The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia.

Chin CK, Leslie C, Grove CS, Van Vliet C, Cheah CY.

Int J Mol Sci. 2017 Sep 22;18(10). pii: E2038. doi: 10.3390/ijms18102038.

27.

Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission.

El-Galaly TC, Cheah CY.

Leuk Lymphoma. 2018 Apr;59(4):775-777. doi: 10.1080/10428194.2017.1365863. Epub 2017 Aug 22. No abstract available.

PMID:
28828884
28.

How I treat patients with aggressive lymphoma at high risk of CNS relapse.

Chin CK, Cheah CY.

Blood. 2017 Aug 17;130(7):867-874. doi: 10.1182/blood-2017-03-737460. Epub 2017 Jun 13. Review.

PMID:
28611025
29.

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.

Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A.

Blood. 2017 Jul 27;130(4):472-477. doi: 10.1182/blood-2017-02-766121. Epub 2017 May 18.

30.

Three different hematologists, three different answers: how should we treat concurrent systemic and central nervous system lymphoma?

Barraclough AA, Cheah CY.

Leuk Lymphoma. 2017 Sep;58(9):1-3. doi: 10.1080/10428194.2017.1307364. Epub 2017 Apr 3. No abstract available.

PMID:
28367720
31.

The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.

El-Galaly TC, Villa D, Michaelsen TY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Johnsen HE, Seymour JF, Connors JM, de Nully Brown P, Bøgsted M, Cheah CY.

Eur J Cancer. 2017 Apr;75:195-203. doi: 10.1016/j.ejca.2016.12.029. Epub 2017 Feb 23.

PMID:
28237865
32.

When to treat patients with relapsed follicular lymphoma.

Cheah CY, Seymour JF.

Expert Rev Hematol. 2017 Mar;10(3):187-191. doi: 10.1080/17474086.2017.1291339. Epub 2017 Feb 15. Review.

PMID:
28164722
33.

Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.

Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH.

Br J Haematol. 2016 Nov;175(3):531-533. doi: 10.1111/bjh.13863. Epub 2015 Dec 18. No abstract available.

PMID:
26683805
34.

Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.

El-Galaly TC, Cheah CY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Poulsen MØ, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Bøgsted M, Johnsen HE, Seymour JF, Connors JM, Brown PD, Villa D.

Br J Haematol. 2016 Dec;175(5):876-883. doi: 10.1111/bjh.14325. Epub 2016 Sep 29.

PMID:
27681999
35.

High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.

Cheah CY, Joske D, Cull G, Gilbertson M, Opat SS, Tam CS, Wirth A, Seymour JF.

Br J Haematol. 2017 Sep;178(6):991-994. doi: 10.1111/bjh.14187. Epub 2016 Jul 29. No abstract available.

PMID:
27470657
36.

Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.

Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA.

Br J Haematol. 2017 Nov;179(3):503-506. doi: 10.1111/bjh.14226. Epub 2016 Jul 5. No abstract available.

37.

Idelalisib in the management of lymphoma.

Cheah CY, Fowler NH.

Blood. 2016 Jul 21;128(3):331-6. doi: 10.1182/blood-2016-02-702761. Epub 2016 Jun 1. Review.

38.

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.

Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA.

JAMA Oncol. 2016 Aug 1;2(8):1065-9. doi: 10.1001/jamaoncol.2016.1396.

PMID:
27227654
39.

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.

Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA.

Am J Hematol. 2016 Sep;91(9):894-9. doi: 10.1002/ajh.24429. Epub 2016 Jun 20.

40.

Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K.

Haematologica. 2016 May;101(5):531-40. doi: 10.3324/haematol.2015.139493. Review.

41.

Engraftment syndrome manifesting as acute brachial neuropathy following high-dose chemotherapy for management of plasma cell myeloma.

Ninkovic S, Cheah CY, Lasocki A, Harrison SJ.

Leuk Lymphoma. 2016 Dec;57(12):2942-2945. Epub 2016 Apr 27. No abstract available.

PMID:
27116896
42.

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.

Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA.

Ann Oncol. 2016 Jul;27(7):1317-23. doi: 10.1093/annonc/mdw169. Epub 2016 Apr 18.

43.

Synchronous biphenotypic Richter syndrome with Epstein-Barr virus-positive nodal classical Hodgkin lymphoma and bone marrow diffuse large B-cell lymphoma.

Cheah CY, Spagnolo D, Frost F, Cull G.

Histopathology. 2016 Oct;69(4):707-10. doi: 10.1111/his.12984. Epub 2016 May 30. No abstract available.

PMID:
27079556
44.

Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma.

Milgrom SA, Cheah CY, Pinnix CC, Smith GL, Dabaja BS, Horace P, Chevez-Barrios P, Fowler NH, Gombos DS.

Leuk Lymphoma. 2016 Nov;57(11):2612-8. doi: 10.3109/10428194.2016.1166490. Epub 2016 Apr 13.

45.

Bacterial Biofilm Infection Detected in Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

Hu H, Johani K, Almatroudi A, Vickery K, Van Natta B, Kadin ME, Brody G, Clemens M, Cheah CY, Lade S, Joshi PA, Prince HM, Deva AK.

Plast Reconstr Surg. 2016 Jun;137(6):1659-69. doi: 10.1097/PRS.0000000000002010.

PMID:
26890506
46.

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.

Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH.

Ann Oncol. 2016 May;27(5):895-901. doi: 10.1093/annonc/mdw026. Epub 2016 Jan 22.

47.

Breakthrough therapies in B-cell non-Hodgkin lymphoma.

Cheah CY, Fowler NH, Wang ML.

Ann Oncol. 2016 May;27(5):778-87. doi: 10.1093/annonc/mdw029. Epub 2016 Jan 22. Review.

48.

Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.

Cheah CY, Mistry HE, Konoplev S, Fowler NH.

Leuk Lymphoma. 2016 Aug;57(8):1974-6. doi: 10.3109/10428194.2015.1124993. Epub 2016 Jan 13. No abstract available.

PMID:
26762971
49.

Mantle Cell Lymphoma.

Cheah CY, Seymour JF, Wang ML.

J Clin Oncol. 2016 Apr 10;34(11):1256-69. doi: 10.1200/JCO.2015.63.5904. Epub 2016 Jan 11. Review.

PMID:
26755518
50.

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.

Cheah CY, Belada D, Fanale MA, Janikova A, Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, Holden S, Seymour JF.

Lancet Haematol. 2015 Apr;2(4):e166-74. doi: 10.1016/S2352-3026(15)00026-5. Epub 2015 Mar 25.

PMID:
26687959

Supplemental Content

Loading ...
Support Center